Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Prescription "Weight Loss" Drugs: Americans Voice an Opinion
Most Americans are aware of the hot prescription drugs associated with weight loss and many are interested in using them. But access and administration are problematic.
The explosion of media around the glucagon like peptide-1 (GLP-1) receptor agonist semaglutide, approved in 2017 as Ozempic for type 2 diabetes and most recently in 2021 as Wegovy for chronic weight management in adults with overweight/obesity shows no signs of abating. Both brand names have become synonymous with shedding pounds.
The most recent Kaiser Family Foundation (KFF) Health Tracking Poll gauged awareness of the weight loss drugs among a representative sample of US adults and asked them whether they had issues with weight and whether they would consider using a "weight loss" medication. Questions then turned to issues including how the drug is administered and insurance coverage and the level of interest in the proposed medications shifted.
Here is a topline look at the findings.
Related Videos
Related Content
Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis
December 2nd 2025Article
Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.
